Clinical trials: Seborrheic Dermatitis
- Condition Seborrheic Dermatitis
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Cradle Cap, Seborrheic Dermatitis
TRIDERM D.S. Crema Normalizzante for Neonatal Hyperseborrhea (Cradle Cap) and Associated Cutaneous Manifestations of Mild-to-Moderate Seborrheic Dermatitis in Children Aged 0 to 3 Years
This clinical study aims to evaluate the effects of using the cosmetic product TRIDERM D.S. Crema Normalizzante in children aged 0 to 3 years with neonatal hyperseborrhea ("cradle cap"), potentially associated with manifestations…
- Trial name
- NCT07860788
- Testing
- TRIDERM D.S. Crema Normalizzante
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- ICIM International S.r.l.
Seborrheic Dermatitis
Efficacy and Safety of Roflumilast Foam 0.3% in Trial Participants With Seborrheic Dermatitis
This study will assess the safety and efficacy of Roflumilast foam 0.3% (ZORYVE®) versus vehicle applied once a day for 8 weeks by trial participants with seborrheic dermatitis.
- Trial name
- NCT07683806
- Testing
- Roflumilast Foam 0.3%, Vehicle foam
- Where
- 52 sites in China
- Volunteers
- 309 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Seborrheic Dermatitis
Long-Term Safety of ARQ-154 Foam in Subjects With Seborrheic Dermatitis
This is an open-label, long-term safety study of roflumilast ARQ-154 foam 0.3% in subjects with seborrheic dermatitis involving up to 20% total Body Surface Area (BSA). Study was applied topically once daily for 52 weeks.
- Trial name
- NCT04445987
- Testing
- ARQ-154
- Where
- 39 sites in United States
- Volunteers
- 408 people
- Sponsor
- Arcutis Biotherapeutics, Inc.
Seborrheic Dermatitis
Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM)
This phase 3, double-blind, vehicle-controlled study assessed the safety and efficacy of roflumilast (ARQ-154) foam 0.3% applied once daily (qd) for 8 weeks by participants with seborrheic dermatitis.
- Trial name
- NCT04973228
- Testing
- Roflumilast Foam, Vehicle Foam
- Where
- 53 sites in United States, Canada
- Volunteers
- 457 people
- Sponsor
- Arcutis Biotherapeutics, Inc.
Seborrheic Dermatitis, Psoriasis of Scalp
Study to Evaluate the Safety of Sebryl® and Sebryl Plus® in Seborrheic Dermatitis and Psoriasis of Scalp
Observational, descriptive, retrospective, multicenter study to evaluate the safety of the treatment with Sebryl® and / or Sebryl Plus® in the management of seborrheic dermatitis and psoriasis of the scalp in routine medical…
- Trial name
- NCT05105139
- Testing
- Allantoin/ Coal Tar/ Clioquinol, Allantoin/ Coal Tar/ Clioquinol/ Triclosan
- Where
- Mexico
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Laboratorios Silanes S.A. de C.V.
Signs of Androgenisation in Women, e.g. Hirsutism, Androgenetic Alopecia, Acne and Seborrhea, Hypersexuality in Men
A Study to Learn About the Awareness and Knowledge That Doctors Have About the Safety and Safe Use Information for Androcur and Other Cyproterone Acetate Treatments in Europe
Androcur is a type of treatment called cyproterone acetate (CPA). Androcur and other CPA treatments work by blocking a group of male sex hormones called androgens in the body.
- Conditions
- Signs of Androgenisation in Women, e.g. Hirsutism, Androgenetic Alopecia, Acne and Seborrhea, Hypersexuality in Men, Sexual Deviations in Men, Prostate Cancer
- Trial name
- Safe-CAM (NCT04925180)
- Testing
- Cyproterone Acetate (Androcur, BAY94-8367)
- Where
- 5 sites in France, Germany and 3 more
- Volunteers
- 600 people
- Sponsor
- Bayer
Cradle Cap, Infantile Seborrheic Dermatitis
Promiseb Topical Cream for Cradle Cap
The purpose of this study is to evaluate the efficacy and safety of Promiseb Topical Cream in cradle cap.
- Trial name
- NCT01214434
- Testing
- Promiseb Topical Cream, Bland emollient
- Where
- 4 sites in United States
- Volunteers
- 42 people
- Sponsor
- Promius Pharma, LLC
Dermatitis, Seborrheic
STUDY TO ASSESS THE LONG-TERM SAFETY OF EXTINA (KETOCONAZOLE) FOAM, 2%
Extina (ketoconazole) Foam, 2% was approved for marketing in the United States (US) in June 2007. Extina foam is indicated for topical treatment of seborrheic dermatitis in immunocompetent patients 12 years of age and older.
- Trial name
- NCT00703846
- Testing
- Ketoconazole
- Volunteers
- 498 people
- Sponsor
- Stiefel, a GSK Company
Seborrheic Dermatitis
Safety and Efficacy Study in Subjects With Seborrheic Dermatitis
The purpose of this study is to determine if two test products are safe and effective in the treatment of seborrheic dermatitis.
- Trial name
- NCT01703793
- Testing
- Test Product 49778, Test Product 10156
- Where
- 22 sites in United States
- Volunteers
- 240 people
- Sponsor
- Medicis Global Service Corporation
Dermatitis, Atopic, Dermatitis, Contact
Efficacy and Tolerability of Prednisolone Acetate 0.5% Cream Versus Betamethasone Valerate 0.1% Cream in Cortisosensitive Dermatosis
Topical corticosteroids are largely used in dermatology. The major problem related to their use is that the same mechanisms underlying their therapeutic effects (antiinflammatory and antiproliferative) may lead to adverse events.
- Conditions
- Dermatitis, Atopic, Dermatitis, Contact, Dermatitis, Seborrheic, Psoriasis
- Trial name
- NCT01011621
- Testing
- 0.5% prednisolone acetate cream, 0.1% betamethasone valerate cream
- Volunteers
- 170 people
- Sponsor
- Mantecorp Industria Quimica e Farmaceutica Ltd.